R100
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 30
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.300
- HYPOXIA+0.280
- MYC_TARGETS_V2+0.260
- WNT_BETA_CATENIN_SIGNALING+0.250
- UNFOLDED_PROTEIN_RESPONSE+0.220
- KRAS_SIGNALING_DN+0.200
- CHOLESTEROL_HOMEOSTASIS+0.180
- APICAL_SURFACE+0.170
- GLYCOLYSIS+0.150
- P53_PATHWAY+0.130
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.600
- INTERFERON_GAMMA_RESPONSE-0.560
- IL6_JAK_STAT3_SIGNALING-0.500
- ALLOGRAFT_REJECTION-0.440
- IL2_STAT5_SIGNALING-0.370
- KRAS_SIGNALING_UP-0.370
- MITOTIC_SPINDLE-0.350
- COMPLEMENT-0.330
- G2M_CHECKPOINT-0.310
- E2F_TARGETS-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD037_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.811 |
| 2 | R22 | — | — | 0.805 |
| 3 | C3L-02163 | — | cohortSQ2 | 0.798 |
| 4 | SRR10900550 | — | — | 0.783 |
| 5 | TCGA-EW-A424-01A-11R-A24H-07 | — | B | 0.773 |
| 6 | SRR815232 | GTEX | — | 0.769 |
| 7 | SRR25617832 | — | B | 0.756 |
| 8 | SRR33532762 | — | C | 0.744 |
| 9 | TCGA-NC-A5HF-01A-11R-A26W-07 | — | cohortSQ1 | 0.744 |
| 10 | MNG1260 | — | — | 0.744 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.300 | Inavolisib | — uncovered |
| HYPOXIA | 0.280 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.260 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.250 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.220 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.180 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.170 | Temsirolimus | — uncovered |
| GLYCOLYSIS | 0.150 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.130 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.080 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.050 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.050 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.040 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.030 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.020 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.010 | Inavolisib | — uncovered |